凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
莱茵生物(002166)公告正文

莱茵生物:2011年第一季度报告全文

公告日期 2011-04-27
股票简称:莱茵生物 股票代码:002166
                                                        桂林莱茵生物科技股份有限公司 2011 年第一季度报告全文




                               桂林莱茵生物科技股份有限公司


                                   2011 年第一季度报告全文

§1 重要提示

    1.1 本公司董事会、监事会及董事、监事、高级管理人员保证本报告所载资料不存在任何虚假记载、
误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性负个别及连带责任。
    1.2 公司第一季度财务报告未经会计师事务所审计。
    1.3 公司负责人秦本军、主管会计工作负责人周庆伟及会计机构负责人(会计主管人员)张为鹏声明:
保证季度报告中财务报告的真实、完整。

§2 公司基本情况

2.1 主要会计数据及财务指标

                                                                                                     单位:元
                                               本报告期末              上年度期末            增减变动(%)
               总资产(元)                       456,621,842.41          548,099,759.28               -16.69%
  归属于上市公司股东的所有者权益(元)            219,421,063.35          226,872,882.59                -3.28%
                股本(股)                        129,533,760.00          129,533,760.00                 0.00%
归属于上市公司股东的每股净资产(元/股)                       1.69                    1.75              -3.43%
                                                本报告期                上年同期             增减变动(%)
            营业总收入(元)                       16,338,684.32             28,204,177.05             -42.07%
    归属于上市公司股东的净利润(元)               -7,445,189.24              2,170,514.07            -443.02%
    经营活动产生的现金流量净额(元)               -2,677,130.83              2,680,955.74            -199.86%
每股经营活动产生的现金流量净额(元/股)                      -0.02                    0.04            -150.00%
         基本每股收益(元/股)                               -0.06                    0.02            -400.00%
         稀释每股收益(元/股)                               -0.06                    0.02            -400.00%
       加权平均净资产收益率(%)                             -3.34%                 0.85%               -4.19%
 扣除非经常性损益后的加权平均净资产收益
                                                             -3.49%                 0.22%               -3.71%
                 率(%)


非经常性损益项目
√ 适用 □ 不适用
                                                                                                     单位:元
                     非经常性损益项目                                 金额                   附注(如适用)
非流动资产处置损益                                                                  0.00
计入当期损益的政府补助,但与公司正常经营业务密切相关,符合
                                                                              373,000.00
国家政策规定、按照一定标准定额或定量持续享受的政府补助除外
除上述各项之外的其他营业外收入和支出                                           31,719.22
所得税影响额                                                                  -55,950.00




                                                                                                              1
                                                           桂林莱茵生物科技股份有限公司 2011 年第一季度报告全文



                            合计                                               348,769.22            -


2.2 报告期末股东总人数及前十名无限售条件股东持股情况表

                                                                                                         单位:股
         报告期末股东总数(户)                                                                             45,825
                                       前十名无限售条件流通股股东持股情况
              股东名称(全称)                期末持有无限售条件流通股的数量                  种类
秦本军                                                               9,653,376 人民币普通股
蒋安明                                                               4,331,576 人民币普通股
姚新德                                                               3,400,402 人民币普通股
张克强                                                                 405,671 人民币普通股
王歧                                                                   157,020 人民币普通股
安海芝                                                                 147,400 人民币普通股
叶美富                                                                 145,300 人民币普通股
郭原平                                                                 133,300 人民币普通股
邢蓉蓉                                                                 132,090 人民币普通股
王龙花                                                                 131,000 人民币普通股


§3 重要事项

3.1 公司主要会计报表项目、财务指标大幅度变动的情况及原因

√ 适用 □ 不适用
3.1.1 报告期内公司资产负债表项目大幅度变动及原因:                                                   单位:元
         项目                      期末余额                     年初余额                      增减比例
   货币资金                           6,545,558.35                 100,027,962.67                           -93%
   预付款项                           1,335,934.93                   4,315,501.33                           -69%
   其他应收款                         7,408,021.44                   5,461,114.76                            36%
   预收款项                             989,930.13                      205,671.26                          381%
   其他应付款                        55,749,880.19                 122,438,436.92                           -54%
   其他非流动负债                    11,521,120.00                   8,821,120.00                            31%
   未分配利润                        -1,896,939.74                   5,548,249.49                          -134%

1、报告期末货币资金相比年初减少 93%,主要系报告期支付工程款、归还借款所致;

2、报告期末预付款项相比年初减少 69%,主要系已取得预付工程及设备款发票所致;

3、报告期末其他应收款相比年初增加 36%,主要系其他往来增加所致;

4、报告期末预收款项相比年初增加 381%,主要系预收客户货款尚未确认收入所致;

5、报告期末其他应付款相比年初减少 54%,主要系归还暂借款所致;

6、报告期末其他非流动负债相比年初增加 31%,主要系取得政府补助增加所致;

7、报告期末未分配利润相比年初减少 134%,主要系报告期亏损所致。




                                                                                                                2
                                                    桂林莱茵生物科技股份有限公司 2011 年第一季度报告全文



3.1.2 报告期内公司利润表项目大幅度变动及原因:                                                单位:元
              项目               本期发生额               上年同期                    增减比例
 营业收入                           16,338,684.32            28,204,177.05                         -42%
 营业成本                           12,594,521.56            20,351,216.41                         -38%
 管理费用                            7,707,503.28             4,292,513.17                          80%
 投资收益(损失以“-”号填列)                  0               144,433.33                        -100%
 汇兑收益(损失以“-”号填列)        -322,071.19               -26,637.63                        1109%
 营业外收入                            407,207.33             1,927,118.12                         -79%
 所得税费用                                     0               541,096.24                        -100%

1、报告期营业收入相比上年同期减少 42%,主要系本期销售收入下滑所致;

2、报告期营业成本相比上年同期减少 38%,主要系报告期收入减少造成成本同比减少所致;

3、报告期管理费用相比上年同期增加 80%,主要系技术公司折旧费、其他运营费用较上年同期增加所致;

4、报告期投资收益相比上年同期减少 100%,主要系参股公司 2010 年度投资分红未在一季度分配所致;

5、报告期汇兑损失相比上年同期增加 1109%,主要系报告期人民币对美元大幅升值所致;

6、报告期营业外收入相比上年同期减少 79%,主要系确认为当期损益的政府补助比上年同期减少所致;

7、报告期所得税费用相比上年同期减少 100%,主要系报告期亏损所致;



3.1.3 报告期内公司现金流量表项目大幅度变动及原因:                                            单位:元
              项目               本期发生额               上年同期                    增减比例
 经营活动产生的现金流量净额         -2,677,130.83             2,680,955.74                        -200%
 投资活动产生的现金流量净额         -4,064,583.70           -11,366,002.63                          64%
 筹资活动产生的现金流量净额        -86,733,023.23            11,309,817.50                        -867%

1、报告期内经营活动产生的现金流量净额相比上年同期减少 200%,主要系报告期费用性支出增加所致;

2、报告期内投资活动产生的现金流量净额相比上年同期增加 64%,主要系报告期技术公司支付工程及设备
款减少所致;

3、报告期内筹资活动产生的现金流量净额相比上年同期减少 867%,主要系报告期银行贷款减少、归还借
款增加所致。



3.2 重大事项进展情况及其影响和解决方案的分析说明

3.2.1 非标意见情况

□ 适用 √ 不适用


3.2.2 公司存在向控股股东或其关联方提供资金、违反规定程序对外提供担保的情况

□ 适用 √ 不适用




                                                                                                         3
                                                           桂林莱茵生物科技股份有限公司 2011 年第一季度报告全文



3.2.3 日常经营重大合同的签署和履行情况

□ 适用 √ 不适用


3.2.4 其他

□ 适用 √ 不适用


3.3 公司、股东及实际控制人承诺事项履行情况

上市公司及其董事、监事和高级管理人员、公司持股 5%以上股东及其实际控制人等有关方在报告期内或持续到报告期内的
以下承诺事项
□ 适用 √ 不适用


3.4 对 2011 年 1-6 月经营业绩的预计

2011 年 1-6 月预计的经营业
                           业绩亏损

2011 年 1-6 月净利润的预计 业绩亏损(万元):                                            700     ~~            1,000
范围
                           公司预计 2011 年 1-6 月亏损 700-1000 万元。

2010 年 1-6 月经营业绩     归属于上市公司股东的净利润(元):                                           -7,724,394.45
                           公司预计随着公司新建生产线得到越来越多客户的认可以及罗汉果提取物通过 FDA 的 GRAS 认证
业绩变动的原因说明         将为公司带来较好的发展机遇。自第 2 季度以来公司销售情况较一季度有了较大的改善,公司
                           预计 2011 年度中期业绩与上年同期亏损额度变动不大。


3.5 其他需说明的重大事项

3.5.1 证券投资情况

□ 适用 √ 不适用


§4 附录

4.1 资产负债表

编制单位:桂林莱茵生物科技股份有限公司                          2011 年 03 月 31 日                        单位:元
                                               期末余额                                   年初余额
             项目
                                       合并               母公司                  合并                  母公司
流动资产:
  货币资金                             6,545,558.35        4,840,658.99        100,027,962.67           97,532,456.19
  结算备付金
  拆出资金
  交易性金融资产
  应收票据
  应收账款                            32,161,218.66       33,017,505.25          36,374,432.99          36,374,432.99
  预付款项                             1,335,934.93        1,040,373.33           4,315,501.33           1,536,554.10




                                                                                                                   4
                                             桂林莱茵生物科技股份有限公司 2011 年第一季度报告全文



  应收保费
  应收分保账款
  应收分保合同准备金
  应收利息
  应收股利
  其他应收款                7,408,021.44      3,131,738.18       5,461,114.76         3,869,061.38
  买入返售金融资产
  存货                     144,137,251.05   143,160,778.18     137,607,908.58       138,326,232.63
  一年内到期的非流动资产
  其他流动资产
流动资产合计               191,587,984.43   185,191,053.93     283,786,920.33       277,638,737.29
非流动资产:
  发放委托贷款及垫款
  可供出售金融资产
  持有至到期投资
  长期应收款
  长期股权投资             26,030,000.00    288,092,270.00      26,030,000.00       287,430,000.00
  投资性房地产
  固定资产                 193,514,575.10   38,101,958.52      192,573,948.04        39,521,944.50
  在建工程                    626,067.00        626,067.00         626,067.00           626,067.00
  工程物资
  固定资产清理
  生产性生物资产
  油气资产
  无形资产                 42,294,335.98    17,607,837.67       42,513,944.01        17,686,390.50
  开发支出
  商誉
  长期待摊费用
  递延所得税资产            2,568,879.90      2,536,351.77       2,568,879.90         2,536,351.77
  其他非流动资产
非流动资产合计             265,033,857.98   346,964,484.96     264,312,838.95       347,800,753.77
资产总计                   456,621,842.41   532,155,538.89     548,099,759.28       625,439,491.06
流动负债:
  短期借款                 99,200,000.00    99,200,000.00      119,200,000.00       119,200,000.00
  向中央银行借款
  吸收存款及同业存放
  拆入资金
  交易性金融负债
  应付票据                    400,000.00        400,000.00         400,000.00           400,000.00
  应付账款                 18,376,389.97      9,758,610.77      20,294,936.90        10,194,277.85
  预收款项                    989,930.13        983,630.13         205,671.26           204,621.26
  卖出回购金融资产款
  应付手续费及佣金



                                                                                               5
                                                           桂林莱茵生物科技股份有限公司 2011 年第一季度报告全文



  应付职工薪酬                           176,101.64           168,263.40                 261,697.90           104,630.26
  应交税费                        -10,487,158.33          -2,423,934.65              -11,669,440.54       -3,619,177.90
  应付利息
  应付股利
  其他应付款                       55,749,880.19          174,593,755.32             122,438,436.92       249,582,695.76
  应付分保账款
  保险合同准备金
  代理买卖证券款
  代理承销证券款
  一年内到期的非流动负债           11,033,724.00              383,724.00             11,033,724.00            383,724.00
  其他流动负债
流动负债合计                      175,438,867.60          283,064,048.97             262,165,026.44       376,450,771.23
非流动负债:
  长期借款                         50,000,000.00                                     50,000,000.00
  应付债券
  长期应付款
  专项应付款
  预计负债
  递延所得税负债
  其他非流动负债                   11,521,120.00            5,996,120.00               8,821,120.00         3,296,120.00
非流动负债合计                     61,521,120.00            5,996,120.00             58,821,120.00          3,296,120.00
负债合计                          236,959,987.60          289,060,168.97             320,986,146.44       379,746,891.23
所有者权益(或股东权益):
  实收资本(或股本)              129,533,760.00          129,533,760.00             129,533,760.00       129,533,760.00
  资本公积                         83,217,530.86          85,883,914.34              83,217,530.86        85,883,914.34
  减:库存股
  专项储备
  盈余公积                          8,573,342.24            8,573,342.24               8,573,342.24         8,573,342.24
  一般风险准备
  未分配利润                       -1,896,939.75          19,104,353.34                5,548,249.49       21,701,583.25
  外币报表折算差额                       -6,630.00
归属于母公司所有者权益合计        219,421,063.35          243,095,369.92             226,872,882.59       245,692,599.83
少数股东权益                             240,791.46                                      240,730.25
所有者权益合计                    219,661,854.81          243,095,369.92             227,113,612.84       245,692,599.83
负债和所有者权益总计              456,621,842.41          532,155,538.89             548,099,759.28       625,439,491.06


4.2 利润表

编制单位:桂林莱茵生物科技股份有限公司                              2011 年 1-3 月                           单位:元
                                               本期金额                                        上期金额
             项目
                                    合并                   母公司                      合并                母公司
一、营业总收入                     16,338,684.32          17,528,522.44              28,204,177.05        28,060,587.31
其中:营业收入                     16,338,684.32          17,528,522.44              28,204,177.05        28,060,587.31




                                                                                                                     6
                                                  桂林莱茵生物科技股份有限公司 2011 年第一季度报告全文



         利息收入
         已赚保费
         手续费及佣金收入
二、营业总成本                    23,866,460.38   20,208,400.38      27,513,544.56        26,327,340.80
其中:营业成本                    12,594,521.56   13,776,710.43      20,351,216.41        20,365,943.15
         利息支出
         手续费及佣金支出
         退保金
         赔付支出净额
         提取保险合同准备金净

         保单红利支出
         分保费用
         营业税金及附加                2,017.04                            2,173.29
         销售费用                  1,418,581.63    1,417,436.55       1,169,583.22         1,169,583.22
         管理费用                  7,707,503.28    3,689,969.30       4,292,513.17         3,093,300.69
         财务费用                  2,143,836.87    1,324,284.10       1,698,058.47         1,698,513.74
         资产减值损失
  加:公允价值变动收益(损失
以“-”号填列)
      投资收益(损失以“-”
                                                                        144,433.33           144,433.33
号填列)
        其中:对联营企业和合
营企业的投资收益
    汇兑收益(损失以“-”号
                                   -322,071.19      -322,071.19         -26,637.63           -26,637.63
填列)
三、营业利润(亏损以“-”号
                                  -7,849,847.25   -3,001,949.13         808,428.19         1,851,042.21
填列)
     加:营业外收入                  407,207.33      407,207.33       1,927,118.12         1,927,118.12
     减:营业外支出                    2,488.11        2,488.11          26,418.73            26,418.73
       其中:非流动资产处置损失                                            5,557.03            5,557.03
四、利润总额(亏损总额以“-”
                                  -7,445,128.03   -2,597,229.91       2,709,127.58         3,751,741.60
号填列)
     减:所得税费用                                                     541,096.24           541,096.24
五、净利润(净亏损以“-”号
                                  -7,445,128.03   -2,597,229.91       2,168,031.34         3,210,645.36
填列)
       归属于母公司所有者的净
                                  -7,445,189.24   -2,597,229.91       2,170,514.07         3,210,645.36
利润
       少数股东损益                      61.21                           -2,482.73
六、每股收益:
       (一)基本每股收益                -0.06                                 0.02
       (二)稀释每股收益                -0.06                                 0.02
七、其他综合收益
八、综合收益总额                  -7,445,128.03   -2,597,229.91       2,168,031.34         3,210,645.36
       归属于母公司所有者的综     -7,445,189.24   -2,597,229.91       2,170,514.07         3,210,645.36




                                                                                                    7
                                                          桂林莱茵生物科技股份有限公司 2011 年第一季度报告全文



合收益总额
    归属于少数股东的综合收
                                             61.21                                     -2,482.73
益总额

本期发生同一控制下企业合并的,被合并方在合并前实现的净利润为:0.00 元。


4.3 现金流量表

编制单位:桂林莱茵生物科技股份有限公司                             2011 年 1-3 月                         单位:元

                                               本期金额                                      上期金额
              项目
                                    合并                  母公司                     合并               母公司
一、经营活动产生的现金流量:
       销售商品、提供劳务收到的
                                   22,242,752.59          22,232,252.59             25,120,751.45       25,020,751.45
现金
    客户存款和同业存放款项
净增加额
       向中央银行借款净增加额
    向其他金融机构拆入资金
净增加额
    收到原保险合同保费取得
的现金
       收到再保险业务现金净额
       保户储金及投资款净增加

       处置交易性金融资产净增
加额
       收取利息、手续费及佣金的
现金
       拆入资金净增加额
       回购业务资金净增加额
       收到的税费返还               2,537,583.59           2,537,583.59                863,484.77          863,484.77
    收到其他与经营活动有关
                                    3,346,247.36           3,208,329.57              3,474,289.26        3,472,545.49
的现金
         经营活动现金流入小计      28,126,583.54          27,978,165.75             29,458,525.48       29,356,781.71
       购买商品、接受劳务支付的
                                   14,853,596.12          18,266,568.97             16,050,017.75       12,446,560.81
现金
       客户贷款及垫款净增加额
    存放中央银行和同业款项
净增加额
    支付原保险合同赔付款项
的现金
       支付利息、手续费及佣金的
现金
       支付保单红利的现金
    支付给职工以及为职工支
                                    5,435,929.69           3,078,786.10              4,865,236.88        4,211,537.05
付的现金
       支付的各项税费                    839,285.32           54,938.05                289,671.19          271,605.77




                                                                                                                  8
                                                  桂林莱茵生物科技股份有限公司 2011 年第一季度报告全文



    支付其他与经营活动有关
                                 9,674,903.24      6,670,320.04       5,572,643.92         5,001,230.79
的现金
      经营活动现金流出小计      30,803,714.37    28,070,613.16       26,777,569.74        21,930,934.42
           经营活动产生的现金
                                -2,677,130.83        -92,447.41       2,680,955.74         7,425,847.29
流量净额
二、投资活动产生的现金流量:
    收回投资收到的现金
    取得投资收益收到的现金                                              144,433.33           144,433.33
    处置固定资产、无形资产和
其他长期资产收回的现金净额
    处置子公司及其他营业单
位收到的现金净额
    收到其他与投资活动有关
的现金
      投资活动现金流入小计                                              144,433.33           144,433.33
    购建固定资产、无形资产和
                                 4,064,583.70        24,525.00       11,510,435.96           142,218.85
其他长期资产支付的现金
    投资支付的现金                                   662,270.00
    质押贷款净增加额
    取得子公司及其他营业单
位支付的现金净额
    支付其他与投资活动有关
的现金
      投资活动现金流出小计       4,064,583.70        686,795.00      11,510,435.96           142,218.85
           投资活动产生的现金
                                -4,064,583.70      -686,795.00      -11,366,002.63             2,214.48
流量净额
  三、筹资活动产生的现金流
量:
    吸收投资收到的现金
    其中:子公司吸收少数股东
投资收到的现金
    取得借款收到的现金                                               90,000,000.00        20,000,000.00
    发行债券收到的现金
    收到其他与筹资活动有关
                                 5,500,000.00    13,500,000.00                            15,000,000.00
的现金
      筹资活动现金流入小计       5,500,000.00    13,500,000.00       90,000,000.00        35,000,000.00
    偿还债务支付的现金          20,000,000.00    20,000,000.00       77,000,000.00        42,000,000.00
    分配股利、利润或偿付利息
                                 2,233,023.23      1,411,518.23       1,690,182.50           953,702.50
支付的现金
    其中:子公司支付给少数股
东的股利、利润
    支付其他与筹资活动有关
                                70,000,000.00    84,000,000.00
的现金
      筹资活动现金流出小计      92,233,023.23    105,411,518.23      78,690,182.50        42,953,702.50
           筹资活动产生的现金
                                -86,733,023.23   -91,911,518.23      11,309,817.50        -7,953,702.50
流量净额
四、汇率变动对现金及现金等价        -7,666.56        -1,036.56           -1,610.75            -1,610.75




                                                                                                    9
                                                    桂林莱茵生物科技股份有限公司 2011 年第一季度报告全文



物的影响
五、现金及现金等价物净增加额      -93,482,404.32   -92,691,797.20       2,623,159.86          -527,251.48
       加:期初现金及现金等价物
                                  100,027,962.67   97,532,456.19       12,974,797.17        12,116,699.14
余额
六、期末现金及现金等价物余额       6,545,558.35     4,840,658.99       15,597,957.03        11,589,447.66


4.4 审计报告

审计意见: 未经审计




                                                                      桂林莱茵生物科技股份有限公司

                                                                            法定代表人:秦本军

                                                                          二○一一年四月二十七日




                                                                                                     10
数据加载中...
prevnext
手机查看股票